- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07581457
Tranexamic Acid in Pediatric Idiopathic Scoliosis Surgery
Efficacy and Safety of Two Intravenous Tranexamic Acid Regimens Versus Placebo in Pediatric Idiopathic Scoliosis Surgery: A Randomized Double-Blind Trial
This study will evaluate whether tranexamic acid (TXA), a medication used to reduce bleeding, is effective and safe in children undergoing surgery for idiopathic scoliosis. Significant blood loss is common during this type of surgery and often requires blood transfusions.
Participants will be randomly assigned to one of three groups: (1) TXA given as an intravenous bolus followed by continuous infusion, (2) TXA given as two intravenous bolus doses, or (3) placebo (saline). Neither the patients nor the medical team will know which treatment is given.
The main goal is to compare how much blood is lost during and after surgery and whether TXA reduces the need for blood transfusions. The study will also assess safety, including the risk of side effects such as seizures or blood clots.
Patients will be followed for up to 30 days after surgery.
Visão geral do estudo
Status
Condições
Descrição detalhada
Posterior spinal fusion for adolescent idiopathic scoliosis is associated with significant intraoperative blood loss and frequent need for blood transfusion. Tranexamic acid (TXA) is an antifibrinolytic agent that reduces bleeding, but optimal dosing strategies in pediatric scoliosis surgery remain unclear.
This study is a prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of two intravenous TXA regimens compared with placebo in children undergoing surgical correction of idiopathic scoliosis.
Participants aged 10-18 years will be randomly assigned to receive either TXA or placebo during surgery. All patients will undergo standardized anesthesia, regional analgesia, and intraoperative neuromonitoring according to institutional protocols.
The primary objective is to assess the effect of TXA on perioperative blood loss. Secondary objectives include evaluation of transfusion requirements, laboratory parameters, and safety outcomes.
Patients will be followed for 30 days after surgery to assess postoperative outcomes and adverse events.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Malgorzata Reysner, MD PhD
- Número de telefone: +48 61 831-01-22
- E-mail: mreysner@ump.edu.pl
Estude backup de contato
- Nome: Piotr Janusz, MD PhD
- E-mail: pjanusz@um.edu.pl
Locais de estudo
-
-
-
Poznan, Polônia, 62-701
- Recrutamento
- Poznan University of Medical Sciences
-
Contato:
- Malgorzata Reysner, M.D. Ph.D.
- Número de telefone: +48 61 873 83 03
- E-mail: mreysner@ump.edu.pl
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age 10 to 18 years
- Diagnosis of idiopathic scoliosis requiring surgical correction (posterior spinal fusion)
- American Society of Anesthesiologists (ASA) physical status I-II
- Written informed consent from parents or legal guardians and assent from the child
Exclusion Criteria:
- Congenital or acquired coagulopathy
- History of thromboembolic disease
- History of seizures or epilepsy
- Known hypersensitivity to tranexamic acid
- Renal insufficiency (estimated glomerular filtration rate < 60 mL/min/1.73 m²)
- Cardiac arrhythmias or cardiovascular disease requiring antiplatelet or anticoagulant therapy
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: TXA Bolus + Infusion
Tranexamic acid administered intravenously as a 15 mg/kg bolus after induction of anesthesia, followed by continuous infusion at 1 mg/kg/h until the end of surgery. Maximum total dose not exceeding 2 g. All patients receive standardized anesthesia (TIVA with propofol and remifentanil), erector spinae plane block, and intraoperative neuromonitoring. |
Tranexamic acid administered intravenously as a 15 mg/kg bolus after induction of anesthesia, followed by continuous infusion at 1 mg/kg/h until the end of surgery.
Outros nomes:
|
|
Comparador de Placebo: Placebo
0.9% sodium chloride (saline) administered intravenously in the same volumes and timing as the active comparator groups (bolus and infusion). All patients receive standardized anesthesia (TIVA with propofol and remifentanil), erector spinae plane block, and intraoperative neuromonitoring. |
Intravenous administration of 0.9% sodium chloride solution used as placebo, matched in volume and timing to the active comparator groups.
Outros nomes:
|
|
Experimental: TXA Bolus Only
Tranexamic acid administered intravenously as two bolus doses: 10 mg/kg after induction of anesthesia and 10 mg/kg 120 minutes after surgical incision or at the beginning of rod placement (whichever occurs first). Maximum total dose not exceeding 2 g. All patients receive standardized anesthesia (TIVA with propofol and remifentanil), erector spinae plane block, and intraoperative neuromonitoring. |
Tranexamic acid administered intravenously as two bolus doses: 10 mg/kg after induction of anesthesia and 10 mg/kg 120 minutes after surgical incision or at the beginning of rod placement, whichever occurs first.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Total Blood Loss
Prazo: 24 hours postoperatively
|
Total blood loss expressed in ml/kg |
24 hours postoperatively
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Total Volume of Blood Transfusion
Prazo: 24 hours postoperatively
|
Total volume of transfused blood products (ml/kg) administered intraoperatively and within the first 24 hours postoperatively. |
24 hours postoperatively
|
|
Hemoglobin Level
Prazo: immediately after surgery (0 hours)
|
Hemoglobin concentration measured in g/dL |
immediately after surgery (0 hours)
|
|
Hemoglobin Level
Prazo: 24 hours postoperatively
|
Hemoglobin concentration measured in g/dL |
24 hours postoperatively
|
|
Hematocrit Level
Prazo: immediately after surgery (0 hours)
|
Hematocrit value (%) |
immediately after surgery (0 hours)
|
|
Hematocrit Level
Prazo: 24 hours postoperatively
|
Hematocrit value (%) |
24 hours postoperatively
|
|
D-dimer Level
Prazo: 24 hours postoperatively
|
Plasma D-dimer concentration measured in mg/L |
24 hours postoperatively
|
|
Fibrinogen Level
Prazo: 24 hours postoperatively
|
Plasma fibrinogen concentration measured in g/L |
24 hours postoperatively
|
|
Prothrombin Time
Prazo: 24 hours postoperatively
|
Prothrombin time measured in seconds |
24 hours postoperatively
|
|
Activated Partial Thromboplastin Time
Prazo: 24 hours postoperatively
|
Activated partial thromboplastin time measured in seconds |
24 hours postoperatively
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Cadeira de estudo: Małgorzata Reysner, MD PhD, Poznan University of Medical Sciences
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças ósseas
- Doenças musculoesqueléticas
- Doenças da coluna vertebral
- Curvaturas da coluna vertebral
- Escoliose
- Produtos químicos orgânicos
- Preparações farmacêuticas
- Ácidos carboxílicos
- Produtos químicos inorgânicos
- Compostos de cloro
- Soluções cristalóides
- Soluções isotônicas
- Soluções
- Ácidos, carbocíclicos
- Ácidos ciclohexanecarboxílicos
- Compostos de sódio
- Cloretos
- Ácido clorídrico
- Ácido Tranexâmico
- Solução salina
- Cloreto de sódio
Outros números de identificação do estudo
- 2/2026
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Individual participant data (IPD) underlying the results reported in this study, after de-identification, will be shared. This includes demographic data, perioperative variables, laboratory results, and outcome measures. Supporting documents such as the study protocol and statistical analysis plan will also be available.
Prazo de Compartilhamento de IPD
Data will be available beginning 6 months after publication of the primary results and ending 5 years after publication.
Critérios de acesso de compartilhamento IPD
Data will be shared with researchers who provide a methodologically sound proposal. Proposals should be directed to the principal investigator. Data access will be granted following approval by the study investigators and after signing a data access agreement.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CIF
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .